The National Institute for Health and Care Excellence (NICE) issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia in Jan 2019. NICE is currently updating this guidance. The new guidance will be published shortly. Until then the NHS should continue to follow the recommendations outlined in the current version of the guidance. The Interventional Procedures Advisory Committee (IPAC) will consider this procedure review and NICE will issue an interventional procedures consultation document about its safety and efficacy for 4 weeks’ public consultation. IPAC will then review the consultation document in the light of comments received and produce a final interventional procedures document, which will be considered by NICE before guidance is issued to the NHS in England, Wales, Scotland and Northern Ireland.
 
Status In progress
Process IP
ID number 1701
Description Prostatic urethral temporary implant insertion aims to relieve symptoms of benign prostatic hyperplasia by creating new channels in the urethra to allow urine to exit the bladder without having the complications of an implant left in situ. It may also reduce the risk of sexual dysfunction. Using local anaesthesia and light sedation, a folded nitinol device is inserted into the prostatic urethra with a cystoscope under direct visualisation. Over the following days, the device deploys in the urethra and the pressure applied by its 3 struts makes ischemic incisions in the prostate and bladder neck and creates new longitudinal channels through which urine can flow. After 5 to 7 days, the device is removed using lidocaine gel and a flexible silicone catheter inserted into the urethra. Both insertion and removal of the device are done as a day case procedure and take about 5 minutes.

Email enquiries


For further information on how we develop guidance, please see our page about NICE interventional procedures guidance